Overall survival (OS) in EBV-positive (study group) and EBV-negative (control group) elderly DLBCL patients in a matched case-control analysis.

<p>Overall survival (OS) in EBV-positive (study group) and EBV-negative (control group) elderly DLBCL patients in a matched case-control analysis.</p

Clinical features and survival outcomes of 16 EBV-positive elderly DLBCL patients.

<p>M, male; F, female; LN, lymph node; IPI, International Prognostic Index; R, Rituximab; CHOP, cyclophosphamide, doxorubicin(may be substituted by epirubicin or peglyated liposome doxorubicin), vincristine,prednisone; EPOCH, etoposide, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; AWD, alive with disease; AND, alive with no evidence of disease; DOD, died of disease.</p><p>Clinical features and survival outcomes of 16 EBV-positive elderly DLBCL patients.</p

Treatment responses and survival outcomes of EBV-positive (study group) and EBV-negative (control group) elderly DLBCL patients.

<p>CR, complete remission; PFS, progression free survival; OS, overall survival.</p><p>Treatment responses and survival outcomes of EBV-positive (study group) and EBV-negative (control group) elderly DLBCL patients.</p

Primary treatment and response in patients with extranodal natural killer (NK)/T-cell lymphoma.

<p>Abbreviations: CRP: C-reactive protein; CT: chemotherapy; RT: radiotherapy; CHOP: cyclophosphamide+doxorubicin+vincristine+prednisone; EPOCH: etoposide+doxorubicin+vincristine+cyclophosphamide+prednisone; ATT: alternating triple therapy (CHOP-B, cyclophosphamide+doxorubicin+vincristine+bleomycin+prednisone; IMVP-16, ifosfamide+methotrexate+etoposide; DHAP, dexamethasone+cisplatin+cytarabine); GEMOX+L-asp: gemcitabine+oxaliplatin+L-asparaginase; SMILE: dexamethasone+methotrexate+ifosfamide+L-asparaginase+etoposide.</p

Univariate and multivariate analysis of prognostic factors for PFS and OS in patients with ENKTL.

<p>Abbreviations: PFS: progression-free survival; OS: overall survival; LN: lymph node; ENKTL: extranodal NK/T-cell lymphoma; RR: relative risk; CI: confidence interval; EUNKTL: extra-upper aerodigestive tract NK/T-cell lymphoma; LDH: lactate dehydrogenase; CRP: C-reactive protein; IPI: International Prognostic Index; KPI: Korean Prognostic Index; ALC: absolute lymphocyte count.</p

Survival outcome of patients according to the Korean Prognostic Index (KPI) score.

<p>(A) Overall survival (OS) according to the KPI for patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type. (B) OS of patients with KPI score = 0–1 according to the new prognostic index. (C) OS of patients with KPI score = 1–2 according to the new prognostic index. (D) OS of patients with KPI score = 2–4 according to the new prognostic index.</p

Survival outcome of patients based on the C-reactive protein (CRP) level.

<p>(A) Progression-free survival (PFS) of patients according to baseline CRP level (≤10 mg/L vs. >10 mg/L). (B) Overall survival (OS) of patients according to baseline CRP level (≤10 mg/L vs. >10 mg/L).</p

Overall survival and relative risk of death according to risk group as defined by the new prognostic index.

a<p>Factors: age >60 years, LDH >245 U/l, CRP>10 mg/L, and albumin <35 g/L.</p><p>Abbreviations: OS: overall survival; RR: relative risk; CI: confidence interval; N/A: not applicable.</p

Typical distributions of BAFF and BAFF-R expression in follicular lymphoma (FL) and representative cases with different immunostaining intensity for BAFF and BAFF-R.

<p>(A) Distribution of BAFF expression in tumor specimen of FL. (B) Distribution of BAFF-R expression in tumor specimen of FL. (C) Negative staining (−) for BAFF. (D) Weak staining (1+) for BAFF. (E) Moderate staining (2+) for BAFF. (F) Strong staining (3+) for BAFF. (G) Negative staining (−) for BAFF-R. (H) Weak staining (1+) for BAFF-R. (I) Moderate staining (2+) for BAFF-R. (J) Strong staining (3+) for BAFF-R.</p

Survival outcome of patients according to the novel prognostic model.

<p>(A) Overall survival (OS) according to the new prognostic index for patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type. (B) OS of patients with low International Prognostic Index risk (IPI score = 0–1) according to the new prognostic index.</p